Physician profile
Kami Tehrani
NPI 1649302290
$4,896.92
in general payments reported to CMS, 2019-2025
31 companies · $641 in 2025
The $641 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $240 · 2021: $708 · 2022: $578 · 2023: $763 · 2024: $1,238 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Education: $109 · Travel and Lodging: $5.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.74 |
| Education | $109.22 |
| Travel and Lodging | $5.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,143.43 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.46 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $477.89 | 2019-2024 | Xarelto |
| Amgen INC. | $453.07 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $303.52 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $229.10 | 2019-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $209.41 | 2025 | Sapien 3 Ultra Resilia |
| Bayer Healthcare Pharmaceuticals INC. | $188.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $175.96 | 2019-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $165.26 | 2019-2024 | |
| Medtronic, INC. | $127.76 | 2024 | Ffrangio |
| Abbott Laboratories | $118.08 | 2024 | Coroflow |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.75 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $96.87 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $80.65 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.59 | 2021-2024 | Verquvo |
| Chiesi USA, INC. | $63.93 | 2019-2023 | Kengreal |
| Amarin Pharma, INC. | $61.76 | 2020-2022 | |
| Esperion Therapeutics, INC. | $47.39 | 2021-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $37.40 | 2024 | Arcalyst |
| Lundbeck LLC | $36.03 | 2019 | |
| Scpharmaceuticals INC. | $34.73 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $23.62 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $21.14 | 2024 | Assure Wcd |
| Amryt Pharma Holdings Ltd | $19.91 | 2021 | |
| Irhythm Technologies, INC. | $19.30 | 2023 | Zio Xt Patch |
| Glaxosmithkline, LLC. | $19.11 | 2025 | Arexvy, Shingrix |
| Alnylam Pharmaceuticals INC. | $18.54 | 2021 | |
| Vifor Pharma, INC. | $16.11 | 2019 | |
| Gilead Sciences, INC. | $12.50 | 2019 | |
| Osprey Medical INC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kami Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.